Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas

Abstract Background Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation. We aimed to determin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2021-11, Vol.23 (11), p.1872-1884
Hauptverfasser:	Yu, Yao, Villanueva-Meyer, Javier, Grimmer, Matthew R, Hilz, Stephanie, Solomon, David A, Choi, Serah, Wahl, Michael, Mazor, Tali, Hong, Chibo, Shai, Anny, Phillips, Joanna J, Wainer, Bruce H, McDermott, Michael, Haas-Kogan, Daphne, Taylor, Jennie W, Butowski, Nicholas, Clarke, Jennifer L, Berger, Mitchel S, Molinaro, Annette M, Chang, Susan M, Costello, Joseph F, Oberheim Bush, Nancy Ann
Format:	Artikel
Sprache:	eng
Schlagworte:	Basic and Translational Investigations Brain Brain Neoplasms - drug therapy Brain Neoplasms - genetics Glioma - drug therapy Glioma - genetics Humans Mutation - drug effects Neoplasm Recurrence, Local - genetics Temozolomide - adverse effects Temozolomide - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!